Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Intarcia Therapeutics

Intarcia Therapeutics?uq=UG6efJS6
1995 FOUNDED
PRIVATE STATUS
201-300 EMPLOYEES
Series EE LATEST DEAL TYPE
$615M LATEST DEAL AMOUNT
41 INVESTORS
Description

Developer of drug therapies that deliver an improved therapeutic outcome while enhancing patients' quality of life. The company's proprietary subcutaneous delivery system comprised of three unique technologies, including a stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures for up to three years or more, a matchstick-sized osmotic mini-pump that is placed just under the dermal layer of skin to deliver a continuous and consistent flow of medication and a placement technology including proprietary tools designed to provide an optimal user experience.

Formerly Known As
BioMedicines
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
  • One Marina Park Drive
  • 13th Floor
  • Boston, MA 02210
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Intarcia Therapeutics’s full profile, request a free trial.

Intarcia Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
22. Later Stage VC (Series EE) 03-Aug-2017 $615M 00.000 00.000 Completed Profitable
21. Later Stage VC (Series DD) 00.000 Completed Profitable
20. Later Stage VC (Series CC) 27-May-2016 00000 00.000 Completed Profitable
19. Debt - General 06-May-2016 0000 00.000 Completed Generating Revenue
18. Convertible Debt 03-Jun-2015 00000 000 Completed Clinical Trials - Phase 3
17. Later Stage VC (Series DD) 27-Mar-2014 00000 00000 00.000 Completed Clinical Trials - Phase 3
16. Later Stage VC (Series B2) 00000 Completed Clinical Trials - Phase 3
15. Later Stage VC (Series B1) 00000 Completed Clinical Trials - Phase 3
14. Later Stage VC (Series AA) 08-Jan-2013 $435M Completed Clinical Trials - Phase 3
13. Later Stage VC (Series CC) 15-Nov-2012 $210M $435M 00000 Completed Clinical Trials - Phase 3
To view this company’s complete deal history including valuation and funding, request access »

Intarcia Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series EE 00,000,000 00.000000 00 000 000 00 000 00.000
Series DD 0,000,000 00.000000 00 000.00 000.00 00 000.00 0.000
Series CC 00,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series BB3 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series BB2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series BB1 3,833,865 $0.001000 8% $6 $6 1x $6 5.6%
Series AA 3,180,135 $0.001000 8% $6 $6 1x $6 4.64%
To view this company’s complete Cap Table, request access »

Intarcia Therapeutics Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 24-Sep-2015 000000000000000000 Drug Discovery 0000 000000
000000000000 01-Apr-2003 00000 00000 00 000.00 Pharmaceuticals
000000000000 01-Nov-2000 00000 00000 00 0000 Pharmaceuticals
Cytokinetics 01-Aug-1999 Early Stage VC 0000 Pharmaceuticals
To view this company’s complete investment and acquisition history, request access »

Intarcia Therapeutics Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000000 01-Apr-2003 00000 00000 00 000.00 Completed
  • 9 buyers
000000000000 01-Nov-2000 00000 00000 00 0000 Completed
  • 6 buyers
Cytokinetics 01-Aug-1999 Early Stage VC 0000 Completed
  • 4 buyers
To view this company’s complete exits history, request access »

Intarcia Therapeutics Investors (41)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Baillie Gifford Venture Capital Minority 000 0000 000000 0
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
Cloudstone Capital Venture Capital Minority 000 0000 000000 0
Cycad Group Venture Capital Minority 000 0000 000000 0
Kayon Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 41 investors. Get the full list »

Intarcia Therapeutics Executive Team (29)

Name Title Board
Seat
Contact
Info
Kurt Graves Chairman, President & Chief Executive Officer
James Ahlers Co-Founder, Chief Financial Officer & Vice President, Finance & Operations
Andy Palan Chief Information Officer
Raymond Keane JD Vice President, General Counsel & Chief Legal Officer
Tom Nuttle Director, Reimbursement Support Services, Health Systems

11 Former Executives

You’re viewing 5 of 29 executives. Get the full list »

Intarcia Therapeutics Board Members (12)

Name Representing Role Since Contact
Info
Bryan Roberts Ph.D Venrock Board Member 000 0000
Edward Mathers New Enterprise Associates Board Member 000 0000
Emad Rizk MD Self Board Member 000 0000
Gino Santini Self Board Member 000 0000
Glen Sato JD Cooley Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »